X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MTP-131 (elamipretide) is an investigational mitochondrial-targeting peptide agent, which is being evaluated for the treatment of patients with barth syndrome.
Lead Product(s): Elamipretide
Therapeutic Area: Rare Diseases and Disorders Product Name: MTP-131
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
The funding will be used to evaluate Stealth's mitochondria-targeted molecule, SBT-272, a novel investigational small molecule that targets cardiolipin, a phospholipid within the inner mitochondrial membrane, for Parkinson's disease
Lead Product(s): SBT-272
Therapeutic Area: Neurology Product Name: SBT-272
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Michael J. Fox Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 09, 2023
Details:
MTP-131 (elamipretide) is an investigational mitochondrial protective agent which is readily penetrates cell membranes and transiently localizes to the inner membrane of the mitochondria where it interacts with cardiolipin and investigated in Patients with Dry AMD.
Lead Product(s): Elamipretide
Therapeutic Area: Ophthalmology Product Name: MTP-131
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Pharmanovia will commercialize MTP-131 (elamipretide), an investigational mitochondrial protective agent, in Europe for the treatment of Barth syndrome, an ultra-rare cardiac condition caused by mitochondrial cardiolipin deficiency for which there are no approved treatments.
Lead Product(s): Elamipretide
Therapeutic Area: Rare Diseases and Disorders Product Name: MTP-131
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Pharmanovia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 30, 2023
Details:
Interim results from the Phase 1 study for SBT-272 demonstrated that selected doses are anticipated to result in therapeutic concentrations in the brain based on observed drug levels achieved in preclinical studies.
Lead Product(s): SBT-272
Therapeutic Area: Neurology Product Name: SBT-272
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
SBT-272 significantly improved mitochondrial structural integrity and motility in TDP-43 mutant (A315T)-expressing upper motor neurons. These enhancements in mitochondrial health were associated with improved axon outgrowth, a key indicator of improved neuronal health.
Lead Product(s): SBT-272
Therapeutic Area: Neurology Product Name: SBT-272
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
ReCLAIM-2 analyses demonstrate that MTP-131 (elamipretide) ameliorated progressive decline, or attenuation, of the mitochondrial rich ellipsoid zone layer of photoreceptors and showed a categorical >2-line improvement in low luminance visual acuity in patients with GA.
Lead Product(s): Elamipretide
Therapeutic Area: Ophthalmology Product Name: MTP-131
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
MTP-131 (elamipretide), is a peptide compound that readily penetrates cell membranes, and targets the inner mitochondrial membrane where it binds reversibly to cardiolipin.
Lead Product(s): Elamipretide
Therapeutic Area: Genetic Disease Product Name: MTP-131
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Elamipretide has been shown to improve frataxin levels in Friedreich's ataxia patient-derived cells and to improve frataxin levels and motor and cardiac function in an animal model of Friedreich's ataxia.
Lead Product(s): Elamipretide
Therapeutic Area: Genetic Disease Product Name: MTP-131
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Results from the 7-week study demonstrated that the combination of weekly PMO and daily MTP-131 (elamipretide) therapies produced more than double the mean level of dystrophin protein in muscles of affected mice compared to treatment with PMO alone.
Lead Product(s): Elamipretide
Therapeutic Area: Genetic Disease Product Name: MTP-131
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
